WO2010053316A3 - Nouvelle utilisation du sixième domaine de type immunoglobuline de vcam-1 - Google Patents

Nouvelle utilisation du sixième domaine de type immunoglobuline de vcam-1 Download PDF

Info

Publication number
WO2010053316A3
WO2010053316A3 PCT/KR2009/006527 KR2009006527W WO2010053316A3 WO 2010053316 A3 WO2010053316 A3 WO 2010053316A3 KR 2009006527 W KR2009006527 W KR 2009006527W WO 2010053316 A3 WO2010053316 A3 WO 2010053316A3
Authority
WO
WIPO (PCT)
Prior art keywords
vcam
immunoglobulin
domain
leukocyte
endothelial cell
Prior art date
Application number
PCT/KR2009/006527
Other languages
English (en)
Other versions
WO2010053316A2 (fr
Inventor
Junho Chung
Seung Eun Choi
Sukmook Lee
In Su Ha
Original Assignee
Snu R&Db Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snu R&Db Foundation filed Critical Snu R&Db Foundation
Publication of WO2010053316A2 publication Critical patent/WO2010053316A2/fr
Publication of WO2010053316A3 publication Critical patent/WO2010053316A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur l'utilisation du sixième domaine de type immunoglobuline de la molécule 1 d'adhésion à une cellule vasculaire (VCAM-1), et plus particulièrement, porte sur un procédé d'inhibition de l'activité du sixième domaine de type immunoglobuline de VCAM-1 pour inhiber la transmigration des leucocytes à travers les cellules endothéliales, et ainsi prévenir ou traiter des maladies médiées par VCAM-1 à l'aide dudit procédé. Selon la présente invention, il est prévu qu'il sera possible non seulement de cribler des matériaux qui peuvent inhiber la transmigration des leucocytes à travers la cellule endothéliale sans affecter la liaison des leucocytes à la cellule endothéliale, mais encore de prévenir ou traiter efficacement des maladies médiées par VCAM-1.
PCT/KR2009/006527 2008-11-06 2009-11-06 Nouvelle utilisation du sixième domaine de type immunoglobuline de vcam-1 WO2010053316A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11187808P 2008-11-06 2008-11-06
US61/111,878 2008-11-06

Publications (2)

Publication Number Publication Date
WO2010053316A2 WO2010053316A2 (fr) 2010-05-14
WO2010053316A3 true WO2010053316A3 (fr) 2010-09-10

Family

ID=42153403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006527 WO2010053316A2 (fr) 2008-11-06 2009-11-06 Nouvelle utilisation du sixième domaine de type immunoglobuline de vcam-1

Country Status (1)

Country Link
WO (1) WO2010053316A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2800066T3 (es) 2010-10-25 2020-12-23 Biogen Ma Inc Procedimientos para determinar diferencias en la actividad de la integrina alfa-4 mediante correlación de diferencias en niveles de sVCAM y/o sMAdCAM

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280941A1 (en) * 2006-05-31 2007-12-06 Junho Chung Vcam-1 specific monoclonal antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280941A1 (en) * 2006-05-31 2007-12-06 Junho Chung Vcam-1 specific monoclonal antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GURUBHAGAVATULA, I. ET AL.: "Engagement of Human PECAM-1 (CD31) on Human Endothelial Cells Increases Intracellular Calcium Ion Concentration and Stimulate Prostacyclin Release", J. CLIN. INVEST., vol. 101, 1998, pages 212 - 222 *
HORACE, M. D. ET AL.: "Platelet Endothelial Cell Adhesion Molecule 1 (PECAM-1/CD31): A Multifunctional Vascular Cell Adhesion Molecule", TRENDS CARDIOVASC. MED., vol. 7, 1997, pages 203 - 210 *
STEWART, J. R. ET AL.: "Vascular Endothelial Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) Expression Is Decreased by TNF-a and IFN-y", THE JOURNAL OF IMMUNOLOGY, vol. 156, 1996, pages 1221 - 1228 *
TARRANT, K. T. ET AL.: "Chemokines and leukocyte trafficking in rheumatoid arthritis", PATHOPHYSIOLOGY, vol. 13, 2006, pages 1 - 14 *

Also Published As

Publication number Publication date
WO2010053316A2 (fr) 2010-05-14

Similar Documents

Publication Publication Date Title
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
BRPI0909346A2 (pt) composição granular de tratamento de tecidos contendo partícula de poliolefina, e, método doméstico de tratamento de tecidos
EP2019677A4 (fr) Aminotétrahydropyranes en tant qu'inhibiteurs de dipeptidyl peptidase-iv pour le traitement ou la prévention du diabète
HK1202429A1 (en) Methods for prevention and treatment of acute renal injury
IL212485A0 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
EP1761532A4 (fr) Aminocyclohexanes en tant qu'inhibiteurs de dipeptidyl peptidase-iv pour le traitement ou la prévention de diabètes
WO2008118711A3 (fr) Procédé d'inhibition de l'activation du complément avec des anticorps anti-facteur c3 humains et son utilisation
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
EP1756106A4 (fr) Derives de la cyclohexylalanine utilises comme inhibiteurs de la dipeptidyl peptidase-iv pour le traitement ou la prevention des diabetes
WO2009117421A3 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
WO2008155533A3 (fr) Composés de traitement
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
EP2331093A4 (fr) Composés, compositions et procédés pour réduire la toxicité et pour traiter ou prévenir des maladies
WO2010068710A3 (fr) Composés inhibiteurs de kinase
WO2012170807A3 (fr) Molécules de liaison anti-psl de pseudomonas et leurs utilisations
IL215592A (en) Compounds, preparations containing them and their uses in the treatment or prevention of conditions in the eyes
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2008043087A3 (fr) Composés hétérocycliques azotés bicycliques pour une utilisation en tant qu'inhibiteurs de stéaroyl-coa-désaturase
WO2010072787A3 (fr) Composition et méthode de traitement d'états pathologiques cutanés
WO2012122070A3 (fr) Barre d'adresse par tâches et mise à l'échelle d'onglets
WO2008121386A3 (fr) Procédés de traitement de troubles intestinaux
WO2009066967A3 (fr) Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer
EP2319521A4 (fr) Composition médicamenteuse brute pour régénération cartilagineuse, soulagement des douleurs et suppression des oedèmes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09824999

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09824999

Country of ref document: EP

Kind code of ref document: A2